Monday, May 21, 2012 11:56:29 AM
Researchers begin an experiment obviously wanting it to succeed, (ie that Bavi works). However, the statistical format is called "the null hypothesis". We are going to hypothesize there is no difference between placebo and Bavi (and hopefully disprove it). Was the null hypothesis, of no difference, proven or disproven here? Probably disproven. It appears that Bavi is the real deal showing improvement, more than doubling overall response rate to medication (ORR), and improving median progression-free survival (PFS) by 50%. Everyone spins these findings differently, but nobody can deny the first impression of a definite anti-cancer effect in Bavi. However, there were only 90 patients in each of the two treatment groups, and the more patients, the greater the reliability of the results, statistically. In this case most experienced researchers with statistical backgrounds would probably say "there appears to be a real difference between Bavi and placebo." Are we sure? How sure? If the pvalue is better than or equal to .05, for instance, that means: If we run 100 tests just like this one the chances of having the same signifantly better results is >95%. So 95 times out of 100 we would be right. Russian roulette with a 100 chamber gun gives you 5 or fewer chances of getting hit. Here's Wikipedia on the subject of pvalue: "In statistical significance testing, the p-value is the probability of obtaining a test statistic at least as extreme as the one that was actually observed, assuming that the null hypothesis is true. In this context, value a is considered more "extreme" than b if a is less likely to occur under the null. One often "rejects the null hypothesis" when the p-value is less than the significance level a (Greek alpha), which is often 0.05 or 0.01. When the null hypothesis is rejected, the result is said to be statistically significant."
Note: all the above is cloaked in negatives, and therefore difficult.
Recent CDMO News
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/15/2024 12:53:01 AM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/12/2024 09:15:31 PM
- Rowley Law PLLC is Investigating Proposed Acquisition of Avid Bioservices, Inc. • PR Newswire (US) • 11/07/2024 10:55:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/07/2024 02:59:47 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/07/2024 02:42:14 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2024 02:11:21 AM
- Avid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion Transaction • GlobeNewswire Inc. • 11/06/2024 11:04:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2024 08:45:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/15/2024 11:40:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/11/2024 11:38:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/11/2024 11:38:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/11/2024 11:37:48 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 10/11/2024 12:22:11 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 10/11/2024 12:21:22 AM
- Avid Bioservices to Participate in Craig-Hallum Bioprocessing Conference • GlobeNewswire Inc. • 09/12/2024 08:05:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/09/2024 08:43:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 08:19:30 PM
- Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024 • GlobeNewswire Inc. • 09/09/2024 08:05:31 PM
- U.S. Futures Rise Amid Inflation Report Anticipation; Oil Prices Climb on Hurricane Threat and Supply Concerns • IH Market News • 09/09/2024 10:09:14 AM
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM